FDA advisory panel unanimously backs biosimilars for Humira, Enbrel
The Food and Drug Administration’s Arthritis Advisory Committee, together with an added complement of dermatologists and gastroenterologists, unanimously recommended during meetings on July 12 and 13...
Source: Family Practice News - Category: Primary Care Source Type: news
More News: Arthritis | Dermatology | Enbrel | Family Practices | Gastroenterology | Humira | Primary Care | Rheumatology | Skin